Sheng Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sheng Yan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jinling Zhang
Wuhan Fourth Hospital, Wuhan Orthopedic Hospital, Wuhan 430033, China
1 shared publication- Ling Hu
Clinical Research Center of Gastroenterology Department, Tianyou Hospital, Affiliated to College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei
1 shared publication Lingzi Zheng
Tianyou Hospital, Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei 430064, China
1 shared publicationWeisen Ning
College of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430065, China
1 shared publication- Xiaoliu Liu
School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China
1 shared publication - Xiaomei Wang
Department of Neurosurgery, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Department of Pharmacy, Institute of Pharmaceutical Process, Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei Province, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101736
Diverse functional roles of miR-128-3p in human diseases: Focus on its roles in human cancer
The microRNA known as miR-128-3p demonstrates widespread tissue-specific expression with its genetic locus situated on human chromosome 2 (2q21.3), and is a multifunctional regulator with tissue-specific expression patterns that critically influences cellular homeostasis and disease pathogenesis. By engaging with the 3′ untranslated region (3′ UTR) of target mRNA molecules, miR-128-3p exquisitely modulates gene expression levels, thereby orchestrating cellular proliferation, immune responses, metabolic equilibrium, and tumorigenesis. Studies on miR-128-3p in different cancers have revealed diverse expression patterns and functional roles. Intriguingly, due to its ability to target multiple genes and signaling pathways, as well as being regulated by various genes themselves, miR-128-3p exhibits both tumor-suppressive and oncogenic effects under neoplastic conditions. This review summarizes the expression patterns and complex regulatory mechanisms of miR-128-3p across various cancers. A profound understanding of the significance and regulation of miR-128-3p in cancer will drive the development of innovative therapeutic strategies using this molecule for combating human cancer and immune-related disorders.
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101736
Open AccessDiverse functional roles of miR-128-3p in human diseases: Focus on its roles in human cancer
The microRNA known as miR-128-3p demonstrates widespread tissue-specific expression with its genetic locus situated on human chromosome 2 (2q21.3), and is a multifunctional regulator with tissue-specific expression patterns that critically influences cellular homeostasis and disease pathogenesis. By engaging with the 3′ untranslated region (3′ UTR) of target mRNA molecules, miR-128-3p exquisitely modulates gene expression levels, thereby orchestrating cellular proliferation, immune responses, metabolic equilibrium, and tumorigenesis. Studies on miR-128-3p in different cancers have revealed diverse expression patterns and functional roles. Intriguingly, due to its ability to target multiple genes and signaling pathways, as well as being regulated by various genes themselves, miR-128-3p exhibits both tumor-suppressive and oncogenic effects under neoplastic conditions. This review summarizes the expression patterns and complex regulatory mechanisms of miR-128-3p across various cancers. A profound understanding of the significance and regulation of miR-128-3p in cancer will drive the development of innovative therapeutic strategies using this molecule for combating human cancer and immune-related disorders.